FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938502016> ?p ?o ?g. }

• W2938502016 endingPage "472" @default.
• W2938502016 startingPage "463" @default.
• W2938502016 abstract "Background: Doravirine is a novel, nonnucleoside reverse transcriptase inhibitor with demonstrated efficacy in treatment-naive adults with HIV-1. Methods: In this open-label, active-controlled, noninferiority trial, adults with HIV-1 virologically suppressed for ≥6 months on 2 nucleoside reverse transcriptase inhibitors plus a boosted protease inhibitor, boosted elvitegravir, or a non-nucleoside reverse transcriptase inhibitor were randomized (2:1) to switch to once-daily, single-tablet doravirine 100 mg with lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF) or to continue their current therapy (Baseline Regimen) for 24 weeks. The primary endpoint was the proportion of participants with HIV-1 RNA <50 copies/mL (defined by the FDA Snapshot approach), with the primary comparison between DOR/3TC/TDF at week 48 and Baseline Regimen at week 24 and a secondary comparison between the groups at week 24 (noninferiority margin, −8%). Results: Six hundred seventy participants (447 DOR/3TC/TDF, 223 Baseline Regimen) were treated and included in the analyses. At week 24, 93.7% on DOR/3TC/TDF vs 94.6% on Baseline Regimen had HIV-1 RNA <50 copies/mL [difference −0.9 (−4.7 to 3.0)]. At week 48, 90.8% on DOR/3TC/TDF had HIV-1 RNA <50 copies/mL, demonstrating noninferiority vs Baseline Regimen at week 24 [difference −3.8 (−7.9 to 0.3)]. In participants on ritonavir-boosted protease inhibitor at entry, mean reductions in fasting LDL-C and non-HDL-C at week 24 were significantly greater for DOR/3TC/TDF vs Baseline Regimen (P < 0.0001). Adverse events occurred in 68.9% on DOR/3TC/TDF and 52.5% on Baseline Regimen by week 24, leading to treatment discontinuation in 2.5% and 0.4%, respectively. Conclusions: Switching to once-daily DOR/3TC/TDF is a generally well-tolerated option for maintaining viral suppression in patients considering a change in therapy. Registration: ClinicalTrials.gov NCT02397096." @default.
• W2938502016 created "2019-04-25" @default.
• W2938502016 creator A5008173217 @default.
• W2938502016 creator A5009542535 @default.
• W2938502016 creator A5014801178 @default.
• W2938502016 creator A5018089266 @default.
• W2938502016 creator A5018127354 @default.
• W2938502016 creator A5018150285 @default.
• W2938502016 creator A5030290095 @default.
• W2938502016 creator A5030830066 @default.
• W2938502016 creator A5046238828 @default.
• W2938502016 creator A5057724971 @default.
• W2938502016 creator A5061097917 @default.
• W2938502016 creator A5083402039 @default.
• W2938502016 creator A5084095018 @default.
• W2938502016 creator A5089424006 @default.
• W2938502016 date "2019-08-01" @default.
• W2938502016 modified "2023-10-01" @default.
• W2938502016 title "Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial" @default.
• W2938502016 cites W2077754502 @default.
• W2938502016 cites W2108276595 @default.
• W2938502016 cites W2116652603 @default.
• W2938502016 cites W2151768713 @default.
• W2938502016 cites W2159584933 @default.
• W2938502016 cites W2256825639 @default.
• W2938502016 cites W2400098683 @default.
• W2938502016 cites W2467253582 @default.
• W2938502016 cites W2550942625 @default.
• W2938502016 cites W2601741382 @default.
• W2938502016 cites W2605932783 @default.
• W2938502016 cites W2762251589 @default.
• W2938502016 cites W2763994526 @default.
• W2938502016 cites W2767089427 @default.
• W2938502016 cites W2781681713 @default.
• W2938502016 cites W2792742326 @default.
• W2938502016 cites W2807931585 @default.
• W2938502016 cites W2889157553 @default.
• W2938502016 doi "https://doi.org/10.1097/qai.0000000000002056" @default.
• W2938502016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6905402" @default.
• W2938502016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30985556" @default.
• W2938502016 hasPublicationYear "2019" @default.
• W2938502016 type Work @default.
• W2938502016 sameAs 2938502016 @default.
• W2938502016 citedByCount "49" @default.
• W2938502016 countsByYear W29385020162019 @default.
• W2938502016 countsByYear W29385020162020 @default.
• W2938502016 countsByYear W29385020162021 @default.
• W2938502016 countsByYear W29385020162022 @default.
• W2938502016 countsByYear W29385020162023 @default.
• W2938502016 crossrefType "journal-article" @default.
• W2938502016 hasAuthorship W2938502016A5008173217 @default.
• W2938502016 hasAuthorship W2938502016A5009542535 @default.
• W2938502016 hasAuthorship W2938502016A5014801178 @default.
• W2938502016 hasAuthorship W2938502016A5018089266 @default.
• W2938502016 hasAuthorship W2938502016A5018127354 @default.
• W2938502016 hasAuthorship W2938502016A5018150285 @default.
• W2938502016 hasAuthorship W2938502016A5030290095 @default.
• W2938502016 hasAuthorship W2938502016A5030830066 @default.
• W2938502016 hasAuthorship W2938502016A5046238828 @default.
• W2938502016 hasAuthorship W2938502016A5057724971 @default.
• W2938502016 hasAuthorship W2938502016A5061097917 @default.
• W2938502016 hasAuthorship W2938502016A5083402039 @default.
• W2938502016 hasAuthorship W2938502016A5084095018 @default.
• W2938502016 hasAuthorship W2938502016A5089424006 @default.
• W2938502016 hasBestOaLocation W29385020161 @default.
• W2938502016 hasConcept C126322002 @default.
• W2938502016 hasConcept C142462285 @default.
• W2938502016 hasConcept C159047783 @default.
• W2938502016 hasConcept C168563851 @default.
• W2938502016 hasConcept C203092338 @default.
• W2938502016 hasConcept C2522874641 @default.
• W2938502016 hasConcept C2777351918 @default.
• W2938502016 hasConcept C2777869810 @default.
• W2938502016 hasConcept C2779298103 @default.
• W2938502016 hasConcept C2780593183 @default.
• W2938502016 hasConcept C2781143361 @default.
• W2938502016 hasConcept C2781413609 @default.
• W2938502016 hasConcept C2781432083 @default.
• W2938502016 hasConcept C2993143319 @default.
• W2938502016 hasConcept C3013748606 @default.
• W2938502016 hasConcept C71924100 @default.
• W2938502016 hasConcept C90924648 @default.
• W2938502016 hasConcept C98274493 @default.
• W2938502016 hasConceptScore W2938502016C126322002 @default.
• W2938502016 hasConceptScore W2938502016C142462285 @default.
• W2938502016 hasConceptScore W2938502016C159047783 @default.
• W2938502016 hasConceptScore W2938502016C168563851 @default.
• W2938502016 hasConceptScore W2938502016C203092338 @default.
• W2938502016 hasConceptScore W2938502016C2522874641 @default.
• W2938502016 hasConceptScore W2938502016C2777351918 @default.
• W2938502016 hasConceptScore W2938502016C2777869810 @default.
• W2938502016 hasConceptScore W2938502016C2779298103 @default.
• W2938502016 hasConceptScore W2938502016C2780593183 @default.
• W2938502016 hasConceptScore W2938502016C2781143361 @default.
• W2938502016 hasConceptScore W2938502016C2781413609 @default.
• W2938502016 hasConceptScore W2938502016C2781432083 @default.
• W2938502016 hasConceptScore W2938502016C2993143319 @default.
• W2938502016 hasConceptScore W2938502016C3013748606 @default.

• next